Compare NSSC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | OGN |
|---|---|---|
| Founded | 1969 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1994 | 2020 |
| Metric | NSSC | OGN |
|---|---|---|
| Price | $37.33 | $13.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $48.17 | $11.40 |
| AVG Volume (30 Days) | 364.5K | ★ 12.1M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.33% | 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | 0.55 |
| Revenue | $181,621,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $13.63 | $0.45 |
| Revenue Next Year | $10.05 | $1.67 |
| P/E Ratio | $52.59 | ★ $24.43 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.44 | $5.69 |
| 52 Week High | $47.61 | $13.48 |
| Indicator | NSSC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 77.13 |
| Support Level | $29.88 | $10.05 |
| Resistance Level | $44.43 | $13.44 |
| Average True Range (ATR) | 1.48 | 0.07 |
| MACD | -0.38 | -0.21 |
| Stochastic Oscillator | 28.28 | 79.07 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.